Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Amagai, Ryo, Kambayashi, Yumi, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913115/
https://www.ncbi.nlm.nih.gov/pubmed/33540765
http://dx.doi.org/10.3390/pharmaceutics13020200
_version_ 1783656730869104640
author Fujimura, Taku
Amagai, Ryo
Kambayashi, Yumi
Aiba, Setsuya
author_facet Fujimura, Taku
Amagai, Ryo
Kambayashi, Yumi
Aiba, Setsuya
author_sort Fujimura, Taku
collection PubMed
description Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.
format Online
Article
Text
id pubmed-7913115
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79131152021-02-28 Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas Fujimura, Taku Amagai, Ryo Kambayashi, Yumi Aiba, Setsuya Pharmaceutics Review Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs. MDPI 2021-02-02 /pmc/articles/PMC7913115/ /pubmed/33540765 http://dx.doi.org/10.3390/pharmaceutics13020200 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fujimura, Taku
Amagai, Ryo
Kambayashi, Yumi
Aiba, Setsuya
Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title_full Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title_fullStr Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title_full_unstemmed Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title_short Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
title_sort topical and systemic formulation options for cutaneous t cell lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913115/
https://www.ncbi.nlm.nih.gov/pubmed/33540765
http://dx.doi.org/10.3390/pharmaceutics13020200
work_keys_str_mv AT fujimurataku topicalandsystemicformulationoptionsforcutaneoustcelllymphomas
AT amagairyo topicalandsystemicformulationoptionsforcutaneoustcelllymphomas
AT kambayashiyumi topicalandsystemicformulationoptionsforcutaneoustcelllymphomas
AT aibasetsuya topicalandsystemicformulationoptionsforcutaneoustcelllymphomas

Ejemplares similares